Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8eaa98d5e195490994072169e9a9f0b2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8eaa98d5e195490994072169e9a9f0b2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8eaa98d5e195490994072169e9a9f0b22021-11-25T17:12:36ZFecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy10.3390/cells101131882073-4409https://doaj.org/article/8eaa98d5e195490994072169e9a9f0b22021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3188https://doaj.org/toc/2073-4409Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn’s disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).Dagmar SchierovaRadka RoubalovaMartin KolarZuzana StehlikovaFilip RobZuzana JackovaStepan CoufalTomas ThonMartin MihulaMartin ModrakMiloslav KverkaLukas BajerKlara KostovcikovaPavel DrastichJana HercogovaMichaela NovakovaMartin VasatkoMilan LukasHelena Tlaskalova-HogenovaZuzana Jiraskova ZakostelskaMDPI AGarticleinflammatory bowel diseasebiological therapytumor necrosis factor-αmicrobiomemycobiomeBiology (General)QH301-705.5ENCells, Vol 10, Iss 3188, p 3188 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
inflammatory bowel disease biological therapy tumor necrosis factor-α microbiome mycobiome Biology (General) QH301-705.5 |
| spellingShingle |
inflammatory bowel disease biological therapy tumor necrosis factor-α microbiome mycobiome Biology (General) QH301-705.5 Dagmar Schierova Radka Roubalova Martin Kolar Zuzana Stehlikova Filip Rob Zuzana Jackova Stepan Coufal Tomas Thon Martin Mihula Martin Modrak Miloslav Kverka Lukas Bajer Klara Kostovcikova Pavel Drastich Jana Hercogova Michaela Novakova Martin Vasatko Milan Lukas Helena Tlaskalova-Hogenova Zuzana Jiraskova Zakostelska Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy |
| description |
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn’s disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC). |
| format |
article |
| author |
Dagmar Schierova Radka Roubalova Martin Kolar Zuzana Stehlikova Filip Rob Zuzana Jackova Stepan Coufal Tomas Thon Martin Mihula Martin Modrak Miloslav Kverka Lukas Bajer Klara Kostovcikova Pavel Drastich Jana Hercogova Michaela Novakova Martin Vasatko Milan Lukas Helena Tlaskalova-Hogenova Zuzana Jiraskova Zakostelska |
| author_facet |
Dagmar Schierova Radka Roubalova Martin Kolar Zuzana Stehlikova Filip Rob Zuzana Jackova Stepan Coufal Tomas Thon Martin Mihula Martin Modrak Miloslav Kverka Lukas Bajer Klara Kostovcikova Pavel Drastich Jana Hercogova Michaela Novakova Martin Vasatko Milan Lukas Helena Tlaskalova-Hogenova Zuzana Jiraskova Zakostelska |
| author_sort |
Dagmar Schierova |
| title |
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy |
| title_short |
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy |
| title_full |
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy |
| title_fullStr |
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy |
| title_full_unstemmed |
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy |
| title_sort |
fecal microbiome changes and specific anti-bacterial response in patients with ibd during anti-tnf therapy |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/8eaa98d5e195490994072169e9a9f0b2 |
| work_keys_str_mv |
AT dagmarschierova fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT radkaroubalova fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT martinkolar fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT zuzanastehlikova fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT filiprob fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT zuzanajackova fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT stepancoufal fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT tomasthon fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT martinmihula fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT martinmodrak fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT miloslavkverka fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT lukasbajer fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT klarakostovcikova fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT paveldrastich fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT janahercogova fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT michaelanovakova fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT martinvasatko fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT milanlukas fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT helenatlaskalovahogenova fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy AT zuzanajiraskovazakostelska fecalmicrobiomechangesandspecificantibacterialresponseinpatientswithibdduringantitnftherapy |
| _version_ |
1718412603306278912 |